MedTrace Logo

Anaplastic Lymphoma Kinase (ALK)-Positive Non-small Cell Lung Cancer (NSCLC) Post-alectinib Treatment Patterns

NCT04351334 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 161

Last updated 2024-09-19

Study results available
· View outcomes & findings →

Summary

This study aims to understand patient profiles, treatment patterns, and clinical outcomes among ALK-positive NSCLC patients treated with alectinib, and post-alectinib treatment patterns and outcomes.

Conditions

  • Non-Small-Cell Lung Carcinoma

Interventions

DRUG

Alectinib

Observational treatment based on physician choice

Sponsors & Collaborators

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-03-01
Primary Completion
2022-11-01
Completion
2022-11-01

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04351334 on ClinicalTrials.gov